1Dr. M. Ito,Dr. M. Yoshida,Dr. K. Obata,Dr. N. Kawai,Dr. M. Udo. Inhibitory control of intracerebellar nuclei by the Purkinje cell axons[J] 1970,Experimental Brain Research(1):64~80
4Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies[J]. Seizure, 2008, 17(5): 405-421.
5Lhatoo SD, Wong IC, Sander JW. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy[J]. Epilepsia, 2000, 41(3): 338-341.
6Chung S, Wang N, Hank N. Comparative, retention rates and long-term tolerability of new antiepileptic drugs[J]. Seizure, 2007, 16(4): 296-304.
7Arif H, Buchsbaum R, Pierro J, et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy[J]. Arch Neurol, 2010, 67(4): 408-415.
8Cramer JA, Mintzer S, Wheless J, et al. Adverse effects of antiepileptic drugs: a brief overview of important issues[J]. Expert Rev Neurother, 2010, 10(6): 885-891.
9Hwang H, Kim H, Kim SH, et al. Long-term effectiveness of ethosuximide,valproic acid,and lamotrigine in childhood absence epilepsy[J]. Brain Dev, 2012, 34(5): 344-348.
10Shawcross D, Knighton S, Bernal W, et al. Old versus new antiepileptic drugs: the SANAD study[J]. Lancet, 2007, 370(9584): 314-315.